BDRXGeneral
▼ -8.5%on this news
Biodexa issues letter to Shareholders
Biodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals for reorganizing the company's share capital at the upcoming Annual General Meeting (AGM). The changes are intended to simplify the existing complex structure of ordinary shares while ensuring that shareholder rights and the number of American Depositary Shares (ADSs) remain unchanged. The AGM will take place on June 17, 2026, where several resolutions, including a reverse stock split and share reclassification, will be proposed. The Board recommends voting in favor of these resolutions to facilitate the capital restructuring.
Read more →BDRXPhases
▲ +42.2%on this news
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Biodexa Pharmaceuticals has announced a partnership with Syngene International to manufacture GMP clinical trial supplies for its drug MTX240. This collaboration marks the second time Syngene has worked with Biodexa, demonstrating their efficiency and flexibility in production timelines. MTX240 utilizes a novel mechanism of action that could address treatment-resistant gastrointestinal stromal tumors (GIST). Biodexa is planning to file an Investigational New Drug application and begin a Phase 1b/2a trial later this year, which will potentially benefit GIST patients who have exhausted existing treatment options.
Read more →BDRXGeneral
Riassunto: Tanner Pharma Group e Biodexa lanciano il programma globale di accesso anticipato per i pazienti affetti da FAP
Tanner Pharma Group and Biodexa Pharmaceuticals have partnered to launch a global access program for eRapa, aimed at patients with familial adenomatous polyposis (FAP). This condition, characterized by polyp proliferation in the colon and rectum, currently lacks an approved therapeutic option. eRapa, an oral formulation of sirolimus, targets mTOR pathways involved in cell growth and proliferation.
Read more →BDRXGeneral
Samenvatting: Tanner Pharma Group en Biodexa lanceren wereldwijd programma voor vroegtijdige toegang voor FAP-patiënten
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to provide global access to eRapa for patients with familial adenomatous polyposis (FAP). FAP is characterized by excessive polyp growth in the colon and rectum, and currently lacks an approved treatment. eRapa, an oral formulation of rapamycin, may offer a new therapeutic option.
Read more →BDRXGeneral
Tanner Pharma Group und Biodexa starten globales Early-Access-Programm für FAP-Patienten
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to launch a global Early-Access Program for eRapa, targeting patients with familial adenomatous polyposis (FAP). This program will allow clinicians to prescribe this investigational therapy outside of clinical trials, addressing a significant unmet medical need. The initiative will also generate real-world data to enhance understanding of FAP and patient experiences.
Read more →BDRXGeneral
Tanner Pharma Group et Biodexa lancent un programme mondial d’accès anticipé destiné aux patients atteints de polypose adénomateuse familiale
Tanner Pharma Group and Biodexa Pharmaceuticals have launched a global access program for eRapa, aimed at patients with familial adenomatous polyposis (PAF). This initiative allows healthcare professionals to prescribe eRapa outside of clinical trials, expanding treatment access. The program also includes the collection of Real World Data to enhance understanding of PAF.
Read more →BDRXGeneral
Resumen: Tanner Pharma Group y Biodexa lanzan un programa de acceso anticipado global para pacientes de poliposis adenomatosa familiar
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic alliance to provide global access to eRapa for patients with familial adenomatous polyposis (FAP). This initiative aims to address the lack of approved therapeutic options for FAP, which typically manifests in adolescence. eRapa, an oral formulation of rapamycin, targets cellular processes involved in tumorigenesis.
Read more →BDRXGeneral
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a Global Early Access Program for eRapa, aimed at patients with Familial Adenomatous Polyposis (FAP). This program allows clinicians to prescribe eRapa outside of clinical trials, addressing a critical need for FAP patients who currently have no approved therapeutic options. Biodexa will also collect Real World Data to enhance understanding of FAP patient challenges.
Read more →BDRXGeneral
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
Biodexa Pharmaceuticals has announced its support for the Life's a Polyp Foundation, the first U.S. advocacy group dedicated to patients with Familial Adenomatous Polyposis (FAP). The foundation aims to empower FAP patients through resources and community support. Biodexa's lead program, eRapa, is currently in a Phase 3 trial, representing a potential non-surgical treatment option for FAP.
Read more →BDRXPhases
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Biodexa Pharmaceuticals has licensed MTX240, a Phase 1 ready drug candidate targeting gastrointestinal stromal tumors (GIST). This novel treatment utilizes a unique molecular glue mechanism, potentially benefiting patients with TKI-resistant disease. The company plans to initiate a Phase 1b/2a study by year-end, focusing on high-need populations.
Read more →BDRXPhases
▼ -10.3%on this news
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Biodexa Pharmaceuticals has announced an exclusive licensing agreement with Otsuka for OPB-171775, now known as MTX240, aimed at treating gastrointestinal stromal tumors (GIST). This novel molecular glue technology is designed to address TKI-resistant cases, offering a new therapeutic option for patients. The compound has shown efficacy in preclinical models and aligns with Biodexa's focus on rare diseases.
Read more →BDRXPhases
▼ -11%on this newsshared move
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Biodexa Pharmaceuticals has announced an exclusive licensing agreement with Otsuka Pharmaceutical for OPB-171775, now known as MTX240, aimed at treating gastrointestinal stromal tumors (GIST). This novel molecular glue has shown promise in overcoming resistance to existing therapies in preclinical models. The compound is expected to address significant unmet medical needs in GIST patients, particularly those resistant to tyrosine kinase inhibitors.
Read more →BDRXGeneral
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Biodexa Pharmaceuticals has appointed Fiona Sharp as Chief Financial Officer and Company Secretary, effective immediately. Sharp, who joined the company in 2019 as Group Financial Controller, has played a vital role in financial governance. Stephen Stamp will remain as CEO while relinquishing his previous roles. The company is focused on developing treatments for unmet medical needs.
Read more →BDRXGeneral
▼ -24%on this news· ran to -41% by day 3
Biodexa Announces Pricing of $10 Million Public Offering
Biodexa Pharmaceuticals PLC has announced the pricing of a public offering amounting to $10 million, which includes 157,000 American depositary shares and 2,891,781 pre-funded units. The company intends to utilize the proceeds for its development programs and general corporate purposes. The offering is anticipated to close on December 19, 2025, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent for this offering, which is registered under the SEC regulations.
Read more →BDRXPhases
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals PLC has announced the enrolment of the first three patients from the University of Bonn into its pivotal Phase 3 Serenta trial for eRapa, targeting familial adenomatous polyposis (FAP). This trial aims to evaluate the safety and efficacy of eRapa, a proprietary oral formulation of rapamycin. The trial, supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, plans to enroll 168 patients in total, with additional sites activating across Europe in the coming months. The development underscores a significant need for less invasive therapies for FAP patients, who currently have limited options beyond surgical interventions.
Read more →BDRXPhases
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals PLC has activated the first European site for its Phase 3 Serenta trial in familial adenomatous polyposis (FAP) at the University of Bonn, Germany. This trial aims to evaluate the efficacy of eRapa in preventing disease progression in FAP patients, who currently have limited treatment options. The activation follows the approval of their Clinical Trial Application by the European Medicines Agency and is supported by a substantial grant from the Cancer Prevention and Research Institute of Texas. Additional European sites are expected to open in the coming months across several countries.
Read more →BDRXPhases
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Biodexa Pharmaceuticals has received approval for a Clinical Trial Application (CTA) from the European Medicines Agency (EMA) for its Phase 3 Serenta trial targeting familial adenomatous polyposis (FAP). The trial will begin enrolling patients in Europe, with the first expected in Q4 2025. The company aims to address a significant unmet medical need in a market valued at $7 billion.
Read more →BDRXConferences/Events
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Biodexa Pharmaceuticals will host a breakfast symposium on FAP mechanisms and chemoprevention trial issues at the CGA-IGC Conference on October 11, 2025. The symposium will feature Dr. Patrick Lynch and an interactive panel discussion with experts from leading institutions. This event coincides with the advancement of Biodexa's Phase 3 Serenta trial for eRapa, aimed at providing new treatment options for FAP patients.
Read more →BDRXGeneral
Interim results for the six months ended June 30, 2025
Biodexa Pharmaceuticals PLC announced its interim results for the six months ending June 30, 2025. The company reported significant progress in its clinical trials, including the enrollment of patients in the pivotal Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP). Despite these advancements, Biodexa faces financial challenges, including net losses and the need for additional funding to sustain operations and development plans.
Read more →BDRXPhases
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has enrolled the first two patients in its pivotal Phase 3 Serenta trial for eRapa, targeting familial adenomatous polyposis (FAP). This trial aims to evaluate eRapa as a non-surgical treatment option for FAP, a condition that typically leads to colorectal cancer. The company sees a significant market opportunity and has received substantial funding to support the trial.
Read more →BDRXGeneral
ADR Ratio Change Effective
Biodexa Pharmaceuticals PLC has announced an effective change in its American Depositary Receipts (ADR) ratio, adjusting from 1 ADR representing 10,000 ordinary shares to 1 ADR representing 100,000 ordinary shares. This change, effective July 31, 2025, will automatically convert existing ADRs at a 1-for-10 ratio. The total number of issued ordinary shares remains unchanged.
Read more →BDRXPhases
▲ +12.1%on this news
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has filed a Clinical Trial Application (CTA) with the EMA for its Phase 3 Serenta trial targeting familial adenomatous polyposis (FAP). This trial aims to evaluate the safety and efficacy of eRapa, a novel treatment for FAP, which has no approved therapeutic options. The trial is expected to begin enrolling patients in Europe by Q4 2025.
Read more →BDRXGeneral
▼ -6.2%on this news
Results of Annual General Meeting
Biodexa Pharmaceuticals PLC announced that all resolutions were passed at its Annual General Meeting held on June 26, 2023. The company is focused on developing innovative treatments for diseases with unmet medical needs, including its lead programs eRapa, tolimidone, and MTX110. The resolutions passed signify shareholder support for the company's strategic direction.
Read more →BDRXGeneral
▼ -6.2%on this newsshared move
Biodexa Pharmaceuticals PLC (" Biodexa " or the " Company ") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative pr
Biodexa Pharmaceuticals PLC announced that all resolutions at its Annual General Meeting were successfully passed. The company, listed on NASDAQ as BDRX, is focused on developing innovative treatments for diseases with unmet medical needs. Its key development programs include eRapa for familial adenomatous polyposis and bladder cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive brain cancers. Biodexa employs proprietary drug delivery technologies to enhance medication bio-distribution.
Read more →BDRXPhases
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has announced the activation of the first clinical study site for its Phase 3 Serenta trial focused on familial adenomatous polyposis (FAP). This trial aims to evaluate the safety and efficacy of eRapa, a potential new treatment for FAP patients. As of now, the trial is actively enrolling participants at the U.S. site, highlighting significant progress in addressing an unmet medical need in this patient population. Additionally, the initiative has received substantial funding support from the Cancer Prevention and Research Institute of Texas.
Read more →BDRXPhases
▲ +6.2%on this newsshared move
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has announced the name 'Serenta' for its upcoming Phase 3 study targeting Familial Adenomatous Polyposis (FAP). The company has also launched a dedicated website to provide resources and information related to the study. This initiative reflects Biodexa's commitment to engaging with the FAP community and advancing its treatment options.
Read more →BDRXPhases
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharmaceuticals has announced the recruitment of the first patient in its Phase 2 study of tolimidone for Type 1 Diabetes. This Investigator Initiated Trial, conducted by the University of Alberta Diabetes Institute, aims to assess important biomarkers related to insulin and blood glucose levels. Previous preclinical studies indicated tolimidone's potential for promoting beta cell proliferation and glycaemic control. The primary objectives of the study include monitoring C-peptide levels and HbA1c after three months against baseline metrics.
Read more →BDRXGeneral
▼ -17.3%on this news
and registered in England and Wales with registered no.
Biodexa Pharmaceuticals PLC will hold its Annual General Meeting on June 26, 2025, in Cardiff, Wales. The meeting will address several ordinary resolutions including the approval of the FY24 Annual Report and the re-election of key directors. The Board has expressed confidence in the effectiveness and commitment of the directors standing for re-election.
Read more →BDRXPhases
▲ +6.9%on this newsshared move
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
Biodexa Pharmaceuticals PLC has announced that its collaboration partner, Emtora Biosciences, has received an additional $3.0 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This funding increases the total support for the Phase 3 program of the drug eRapa in treating familial adenomatous polyposis to $20.0 million. The Phase 3 trial, a double-blind placebo-controlled study involving 168 patients, is set to begin recruitment in the coming weeks across 30 clinical sites in the US and Europe. eRapa aims to provide a new treatment option for patients who currently have limited choices for managing this hereditary condition.
Read more →BDRXGeneral
▲ +6.9%on this newsshared move
NOTICE OF GENERAL MEETING BIODEXA PHARMACEUTICALS PLC (Incorporated and registered in England and Wales with registered no. 09216368) Notice is hereby given that a general meeting (" GM ") of the members of Biodexa Pharm
Biodexa Pharmaceuticals PLC has announced a general meeting set for June 11, 2025, to discuss several proposed resolutions. Key items on the agenda include the subdivision of existing shares and the issuance of new shares without pre-emption rights. The meeting aims to facilitate a share capital reorganization and authorize the directors to allot new shares as part of the company's strategy to diversify its development pipeline in rare and oncology products. The proposed amendments to articles of association will also be addressed in conjunction with these resolutions.
Read more →BDRXGeneral
▲ +6.9%on this newsshared move
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
Biodexa Pharmaceuticals PLC has announced a Notice of General Meeting scheduled for June 11, 2025, to propose four resolutions regarding its share structure and company articles. These resolutions include subdividing ordinary shares and granting directors authority to allot shares, with the intent to lower the shares' par value. The company, known for its innovative treatments for conditions such as type 1 diabetes and cancer, continues to focus on addressing unmet medical needs through its clinical programs.
Read more →BDRXPhases
▼ -12.8%on this news
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
Biodexa Pharmaceuticals PLC has announced the grant of Orphan Drug Designation for its drug eRapa in Europe for the treatment of familial adenomatous polyposis (FAP). The designation follows a similar approval from the FDA in the United States in 2019. Biodexa is preparing for a Phase 3 study, which is expected to involve 168 patients across 30 clinical sites. The study is supported by significant funding aimed at exploring the therapeutic potential of eRapa for patients affected by FAP, a condition with no existing pharmaceutical treatment options.
Read more →BDRXFDA Updates
▼ -6.6%on this news
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Biodexa Pharmaceuticals PLC has announced a positive outcome from its Type C meeting with the FDA regarding the Phase 3 study protocol for eRapa in familial adenomatous polyposis (FAP). This approval clears the way for finalizing the Phase 3 protocol and recruiting clinical sites in the U.S. The study will involve a double-blind placebo-controlled trial of 168 patients and is supported by significant funding from the Cancer Prevention Research Institute of Texas. The company is optimistic about initiating the registrational Phase 3 study in the U.S. in the coming quarter.
Read more →BDRXPhases
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Biodexa Pharmaceuticals has appointed Precision for Medicine LLC as the clinical research organization for the European section of a Phase 3 study of eRapa in treating Familial Adenomatous Polyposis (FAP). The trial will be a double-blind, placebo-controlled study involving 168 patients at approximately 30 sites in the US and Europe. Precision brings over 20 years of expertise in rare disease clinical trials, which is expected to accelerate the development process for eRapa. The company aims to address unmet medical needs in the management of FAP with this innovative treatment approach.
Read more →BDRXPhases
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
Biodexa Pharmaceuticals PLC announced the allowance of a U.S. patent for its oral rapamycin nanoparticle preparations, named eRapa. The patent is set to be issued on March 4, 2025, providing an additional layer of exclusivity for eRapa, which is aimed at treating Familial Adenomatous Polyposis (FAP). The company plans to initiate a Phase 3 registrational study of eRapa next quarter, significantly funded by a $17.0 million grant. eRapa is being developed as a novel treatment for FAP associated with mTOR pathway activation.
Read more →BDRXConferences/Events
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Biodexa Pharmaceuticals PLC is scheduled to present at the Emerging Growth Conference on February 19, 2025. The company will host a live, interactive online event that allows shareholders and other investors to engage with CEO/CFO Stephen Stamp. Attendees can submit questions both prior to and during the presentation, which will focus on Biodexa's pipeline of innovative biopharmaceutical products. The event aims to highlight the company's developments in addressing unmet medical needs.
Read more →BDRXFDA Updates
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals has received Fast Track designation from the US FDA for eRapa, its encapsulated form of rapamycin, aimed at treating familial adenomatous polyposis (FAP). This designation acknowledges the unmet medical need for therapeutic alternatives in FAP, which currently only has surgical options. The Phase 2 study indicated eRapa's safety and efficacy, showing a median 17% reduction in polyp burden and a significant non-progression rate. Biodexa also plans to pursue Orphan Drug designation in Europe.
Read more →BDRXGeneral
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
Biodexa Pharmaceuticals PLC has appointed Dr. Gary A. Shangold as Chief Medical Officer. This strategic move is intended to bolster the company's management team as it prepares for a crucial Phase 3 registrational study in Familial Adenomatous Polyposis (FAP). Dr. Shangold possesses significant experience across various therapeutic areas, previously serving as Chief Medical Officer at Enteris BioPharma and Xanodyne Pharmaceuticals. His expertise is expected to aid Biodexa in navigating the later phases of clinical development for its pipeline of innovative treatments.
Read more →BDRXGeneral
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
Biodexa Pharmaceuticals PLC has announced that it has regained compliance with the Nasdaq's minimum bid price requirement for continued listing, following notification from the Nasdaq Hearings Panel. Initially, the company faced non-compliance but received an exception to demonstrate compliance through the end of October 2024. Biodexa is currently developing innovative products like eRapa, tolimidone, and MTX110 for serious medical conditions, supported by their proprietary drug delivery technologies. The company remains subject to monitoring until February 2025.
Read more →BDRXGeneral
Biodexa Announces Successful Appeal of Nasdaq Delisting
Biodexa Pharmaceuticals PLC announced a successful appeal against its delisting from Nasdaq, receiving an extension to meet minimum bid price compliance. The Nasdaq Hearings Panel granted the Company until October 31, 2024, to maintain a closing bid price of at least $1.00 per share for 20 consecutive trading days. Biodexa is engaged in developing innovative products targeting various diseases, including its lead programs for Familial Adenomatous Polyposis and type 1 diabetes.
Read more →BDRXPhases
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
Biodexa Pharmaceuticals has provided an update on its Phase 1 study of MTX110 for recurrent glioblastoma, highlighting progression-free and overall survival outcomes from the study's Cohort A. Despite the unfortunate deaths of two patients, the results indicate that survival rates are promising compared to existing benchmarks. The study utilizes MTX110, delivered via convection-enhanced delivery, which offers a novel approach to bypass the blood-brain barrier. Further evaluations will continue as the company seeks to establish the efficacy of this treatment in this aggressive cancer indication.
Read more →BDRXGeneral
It is commonly abbreviated as CIK.
The article focuses on technical definitions and references related to the Entity Central Index Key (CIK) as used in SEC filings. It provides a detailed explanation of various terms associated with document submissions but does not include recent news or updates on Biodexa Pharmaceuticals PLC. The text appears to be more of a technical reference than an informative news piece about the company.
Read more →BDRXPhases
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada
Biodexa Pharmaceuticals PLC has received approval from Health Canada to initiate a Phase 2a study of tolimidone for treating Type 1 diabetes. The study will be led by the University of Alberta and will assess C-peptide and HbA1c levels in patients. The first patient enrollment is expected within the current quarter. Tolimidone, a previously investigated compound, has shown potential for glucose modulation and beta cell proliferation in earlier preclinical studies.
Read more →BDRXPhases
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals announced positive results from a Phase 2 clinical trial of eRapa in treating Familial Adenomatous Polyposis (FAP). At 12 months, a 75% non-progression rate and a median polyp burden reduction of 17% were observed. Cohort 2 showed even more promising results, with an 81% non-progression rate and a 29% median reduction in polyp burden. The company plans to move forward with a Phase 3 registrational study supported by grant funding from the Cancer Prevention and Research Institute of Texas.
Read more →BDRXGeneral
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
Biodexa Pharmaceuticals PLC announced that it has raised $7 million through the exercise of warrants, which will fully cover its first-year obligations for the Phase 3 trial of eRapa in treating Familial Adenomatous Polyposis. This funding is expected to unlock an additional $17 million in non-dilutive grant funding through a matching program. The positive trial data showing a statistically significant decrease in polyp burden strengthens the company's position in tackling rare diseases. The exercise of warrants will result in new warrants provided to existing investors for further capital raise opportunities.
Read more →BDRXPhases
Biodexa Pharmaceuticals PLC?Annual Report and Accounts 2023Biodexa Pharmaceuticals PLCAnnual Report and Accounts 2023
Biodexa Pharmaceuticals PLC has released its Annual Report for 2023, highlighting the company's strategic repositioning from a drug delivery platform to a therapeutics company. The report emphasizes the completion of patient recruitment for several clinical studies, including Phase I trials for its lead product MTX110 in recurrent glioblastoma and a planned Phase IIa study for tolimidone in Type 1 diabetes. Despite the positive advancements, the company faces challenges in funding and developing its assets, especially since tolimidone was previously abandoned by Pfizer. The report outlines Biodexa's strategy to focus on delivering proof-of-concept data as it moves forward.
Read more →BDRXPhases
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals' licensor, Emtora Biosciences, will present Phase 2 trial results of eRapa in treating Familial Adenomatous Polyposis (FAP) at the 2024 Digestive Disease Week. This presentation is scheduled for May 18-21, and is significant as FAP has no current approved treatment options. eRapa, an innovative oral formulation of rapamycin, aims to lessen known issues with bioavailability and toxicity found in existing treatments. The company has entered into a definitive agreement for the exclusive rights to further develop eRapa, which has received Orphan Designation in the US and is under consideration in Europe.
Read more →BDRXPhases
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has entered into an exclusive license agreement with Emtora Biosciences for its Phase 3 ready asset, eRapa, aimed at treating Familial Adenomatous Polyposis (FAP). This deal includes $17 million in grant funding from the Cancer Prevention and Research Institute of Texas to support a pivotal Phase 3 trial. FAP is a genetic condition with no approved therapeutic options, making eRapa's potential to prevent surgical intervention particularly significant. The company is also exploring other indications for eRapa, including bladder and prostate cancers.
Read more →BDRXGeneral
April 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a cl
Biodexa Pharmaceuticals PLC has announced its preliminary results for the year ended December 31, 2023, revealing progress in its clinical pipeline targeting primary and metastatic brain cancers. The company aims to advance its clinical-stage assets, including MTX110 and tolimidone, with specific priorities set for 2024. Biodexa's focus includes obtaining IND for MTX110 and initiating a Phase IIa study for tolimidone in Type 1 diabetes. Despite facing challenges in funding and market positioning, the company remains committed to its innovative treatment developments.
Read more →BDRXPhases
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Biodexa Pharmaceuticals has reported positive top-line results from a Phase I clinical trial of MTX110 for treating diffuse midline glioma, showing a median overall survival of 16.5 months, significantly higher than a comparable cohort. The company is planning to present detailed trial results at the International Symposium on Pediatric Neuro-Oncology in 2024. Additionally, Biodexa's preclinical assessment of tolimidone for Type 1 diabetes did not yield conclusive results, prompting the company to pursue further in vivo studies.
Read more →BDRXPhases
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Biodexa Pharmaceuticals has reported a notable survival outcome from its MAGIC-G1 study of MTX110 in recurrent glioblastoma patients. In this Phase I study, one patient achieved 12 months of survival following treatment with MTX110, with no adverse events noted in the initial treatment period. The study aims to assess the safety and feasibility of a novel delivery method for this anti-cancer agent, which is designed to overcome barriers posed by traditional treatments. The ongoing research reflects Biodexa's commitment to addressing urgent medical needs in glioblastoma treatment.
Read more →BDRXPhases
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
Biodexa Pharmaceuticals PLC has announced the allowance of a U.S. patent for tolimidone, which is intended for use in treating Type 1 diabetes. The company aims to initiate a Phase 2 clinical program for tolimidone, following positive preclinical results that indicate its potential to enhance beta cell survival. The safety of tolimidone has been validated in studies involving over 700 patients. The patent grant is expected to provide Biodexa with market exclusivity for the drug in the U.S.
Read more →BDRXGeneral
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Biodexa Pharmaceuticals has released a shareholder letter detailing the company's achievements in 2023 and its anticipated milestones for 2024. Key highlights include the completion of its transition to a NASDAQ-listed company and the successful in-licensing of tolimidone for Type 1 diabetes treatment. The letter emphasizes ongoing clinical studies in various oncology programs, including glioblastoma multiforme and pediatric brain cancers, and presents an optimistic outlook for data releases in the coming year. Overall, Biodexa's development pipeline has been bolstered, positioning it for future growth and success.
Read more →BDRXGeneral
Biodexa Appoints Ann Merchant to the Board of Directors
Biodexa Pharmaceuticals PLC has appointed Ann Merchant as a Non-executive Director effective December 31, 2023. Merchant, who has a strong background in the biopharmaceutical industry, previously served as Vice President at MorphoSys and has held various positions at Amgen. The Chairman of Biodexa, Dr. Stephen Parker, expressed optimism about her extensive operational experience enhancing the Board's capabilities. Biodexa is actively developing innovative treatments for conditions like Type 1 diabetes and rare brain cancers.
Read more →BDRXGeneral
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Biodexa Pharmaceuticals PLC announced the closure of a $6.0 million underwritten public offering, which included the full exercise of the overallotment option. Alongside this, the company secured exclusive worldwide rights to Tolimidone, a compound previously developed by Pfizer for gastric ulcers and now poised for a Phase II program targeting Type I diabetes. The offering was well-received, highlighting investor confidence, but Tolimidone's earlier discontinuation by Pfizer raises questions about its future efficacy in clinical trials. Biodexa's focus remains on developing treatments for unmet medical needs, particularly in oncology.
Read more →BDRXGeneral
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company deve
Biodexa Pharmaceuticals PLC has announced the pricing of a $5.2 million underwritten public offering of units, which includes Class A and Class B Units. The offering is expected to close around December 21, 2023, pending customary closing conditions. The funds raised will support the company's development of innovative biopharmaceuticals aimed at treating diseases with unmet medical needs, particularly in the oncology sector. The offering includes various types of warrants and pre-funded warrants attached to the units being sold.
Read more →BDRXGeneral
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
Biodexa Pharmaceuticals PLC has announced the pricing of a $5.2 million underwritten public offering, which is set to include Class A and Class B units. The Class A Units are priced at $2.00 each and include warrants, while the Class B Units are offered at approximately $1.9999 each and consist of pre-funded warrants and other warrants. The offering marks a significant step in Biodexa's efforts to further develop its pipeline targeting primary and metastatic brain cancers. The closing of the offering is expected to occur on or about December 21, 2023, pending customary conditions.
Read more →BDRXGeneral
November 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes Highlights: Acquisiti
Biodexa Pharmaceuticals has announced an agreement to acquire exclusive worldwide rights to tolimidone, a Phase II ready asset for Type 1 diabetes. This drug, previously developed by Pfizer for gastric ulcers, has demonstrated potential in enhancing beta cell survival and proliferation. Biodexa plans to initiate a Phase Ib dose confirmation study, followed by a Phase II clinical trial to evaluate its efficacy in Type 1 diabetes patients. The transaction is expected to close in the fourth quarter of 2023, thereby expanding Biodexa's pipeline in diabetes management.
Read more →BDRXGeneral
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC has announced the acquisition of an exclusive worldwide license for tolimidone, a Phase II ready asset intended for the treatment of Type 1 Diabetes (T1D). The drug displays promising preclinical results in promoting beta cell proliferation, which is critical for insulin production. Biodexa plans to initiate a Phase Ib dose confirmation study in collaboration with the Alberta Diabetes Institute, with the aim of establishing the minimum effective dose for T1D patients. While the acquisition strengthens Biodexa's pipeline, tolimidone's prior development history includes discontinued trials due to efficacy concerns.
Read more →BDRXPhases
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC has completed recruitment for cohort A of its Phase 1 study of MTX110 in patients with recurrent glioblastoma. The study, MAGIC-G1, is evaluating the feasibility and safety of delivering MTX110 via convection enhanced delivery. Initial results are promising, with no dose-limiting toxicities reported, and cohort B enrollment is expected to begin following approval from the Data Safety Monitoring Board. The findings underline Biodexa's commitment to developing effective treatments for aggressive brain cancers.
Read more →BDRXPhases
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
Biodexa Pharmaceuticals PLC is set to present an update on its Phase 1 study of MTX-110 for recurrent glioblastoma at the upcoming EANO meeting. The MAGIC-G1 study has successfully dosed three patients in its first cohort without any observed dose-limiting toxicities, suggesting a well-tolerated treatment regime. Designed as an open-label, dose escalation study, it aims to explore safety and feasibility through intermittent infusions via a specialized delivery method. The company expresses optimism about the study’s progress and its potential impact on a disease with significant unmet medical need.
Read more →BDRXGeneral
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
Biodexa Pharmaceuticals PLC has launched a new corporate website and a patient-focused site to provide information about its ongoing clinical trials. The corporate website highlights the company's transformation into a drug development firm specializing in rare diseases and oncology. The clinical trials site aims to help potential participants understand the trial process and assess their eligibility. These initiatives signify Biodexa's commitment to advancing therapies for patients with brain cancers.
Read more →BDRXGeneral
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC has confirmed its compliance with NASDAQ's minimum bid price requirement, allowing its securities to remain listed on the exchange. The previously scheduled hearing with the NASDAQ Hearing Panel has been cancelled due to this compliance. However, the company will be under a Mandatory Panel Monitor for a year, and non-compliance within this period could result in a delisting determination. Biodexa focuses on developing treatments for brain cancers, including its lead candidate, MTX110.
Read more →BDRXGeneral
June 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Receipt of NASDAQ Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developi
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has received a delisting determination from Nasdaq due to its securities trading below the $0.10 threshold for ten consecutive days. The company has been granted a 180-day compliance period, which ends on July 31, 2023. If compliance is not achieved, the company risks further delisting. Biodexa plans to appeal the determination to a Hearings Panel to avoid immediate suspension and continue monitoring its stock performance.
Read more →BDRXPhases
Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022
Biodexa Pharmaceuticals PLC, headquartered in Cardiff and listed on NASDAQ, has repositioned itself from a drug delivery company to a therapeutics company focused on rare and orphan brain cancers. The strategic review revealed challenges including unmet partnership opportunities and insufficient financing, leading to a $6 million fundraising effort. The company has initiated a Phase I study for its clinical-stage asset, MTX110, signaling progress despite setbacks in its merger plans and internal R&D collaborations.
Read more →BDRXGeneral
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
Biodexa Pharmaceuticals PLC has successfully closed a registered direct offering, raising $3.32 million to support its operations. The company plans to use the proceeds for working capital and general purposes, ensuring sufficient cash flow into early 2024. The offering included Series C and D warrants, expanding investment options for purchasers. The transaction, facilitated by Ladenburg Thalmann & Co., Inc., indicates a strategic approach to fund further developments in Biodexa's pipeline, particularly in targeting serious brain cancer indications.
Read more →BDRXGeneral
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
Biodexa Pharmaceuticals PLC has announced a successful Registered Direct Offering, raising approximately US$3.32 million to support its business activities. The funds will be allocated for working capital and general corporate purposes, enabling the company to maintain operations into early 2024. However, if the offering is not completed, the company may struggle to secure alternative funding, which could jeopardize its ongoing projects and financial viability.
Read more →BDRXGeneral
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE
Biodexa Pharmaceuticals PLC announced a registered direct offering in the U.S. that raised approximately US$3.32 million through the issuance of new American Depositary Shares. The company plans to use the net proceeds for working capital, expecting them to sustain operations into the first quarter of 2024. However, if this offering does not close, Biodexa may face urgent challenges in securing alternative funding and could jeopardize its ongoing projects.
Read more →BDRXGeneral
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
Biodexa Pharmaceuticals has signed a non-binding letter of intent to acquire Varian Biopharmaceuticals, shifting its strategy towards therapeutics. The acquisition aims to enhance Biodexa's pipeline with VarianBio's innovative oncology products, particularly targeting various cancer types through its lead compounds, VAR-101 and VAR-102. The deal proposes an ownership distribution plan for VarianBio's security holders and aims to raise funding to support ongoing developmental studies. This acquisition represents a significant step in Biodexa's evolution towards a fully-integrated therapeutics company.
Read more →BDRXGeneral
April 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a cl
Biodexa Pharmaceuticals PLC reported its audited preliminary results for the year ended December 31, 2022, focusing on its clinical-stage biopharmaceutical development. The company is concentrating on the development of MTX110 for treating aggressive brain cancers, with successful patient recruitment into its Phase I study. Biodexa experienced challenges in finding partnerships for its internal pipeline and had to terminate certain programs. However, it raised $6 million for its strategic repositioning towards therapeutics in the rare and orphan disease space.
Read more →BDRXGeneral
April 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Exercise of Pre-Funded Warrants and Issue of Equity Total Voting Rights Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX), a drug delivery technolog
Biodexa Pharmaceuticals PLC has announced the exercise of 1,255,093 Pre-Funded Warrants leading to the issuance of 6,275,465 new ordinary shares at a gross proceeds of $502.04. These shares are expected to start trading on AIM on April 25, 2023. The company's enlarged share capital will consist of 94,629,412 ordinary shares, each with voting rights, which may affect shareholder notification requirements regarding their interests. This exercise reflects the company's ongoing efforts to improve its financial position and enhance its drug delivery capabilities.
Read more →BDRXGeneral
▼ -11.2%on this news· ran to -42% by day 3
March 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Exercise of Warrants and Issue of Equity Total Voting Rights Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX), a drug delivery technology company f
Biodexa Pharmaceuticals PLC has announced the exercise of warrants leading to the issuance of 6,218,265 new ordinary shares. This increase in equity is part of the exercise of B Warrants received by the company. All warrants have been exercised on a cashless basis, further positioning the company for future growth. The newly issued shares will rank pari passu with existing shares, and trading is expected to commence on April 5, 2023.
Read more →BDRXPhases
March 2023 Midatech Pharma PLC ("Midatech" or the "Company") New Preclinical R&D Programme Focused on Leptomeningeal Disease Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on i
Midatech Pharma PLC has announced the initiation of a new preclinical R&D program, MTD217, aimed at developing treatments for leptomeningeal disease, a severe complication in metastatic cancers. The program focuses on the simultaneous inhibition of key metabolic pathways to improve therapeutic efficacy and reduce off-target toxicity. Initial in vitro results have shown significant synergistic effects with existing drugs, and the company is working towards generating proof of concept data for future clinical trials. With the establishment of new patent protections, Midatech is positioning itself to capitalize on its innovations in drug delivery technology.
Read more →BDRXGeneral
March 2023 Midatech Pharma PLC (" Midatech " or the " Company ") Results of General Meeting Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM Midatech Pharma PL
Midatech Pharma PLC announced the successful resolutions from its general meeting, including a share consolidation and a name change to Biodexa Pharmaceuticals PLC. Shareholders approved the consolidation, where every 20 ordinary shares will convert to one new share. The company will continue trading on NASDAQ while its AIM listing will be canceled around late April 2023. The changes are expected to streamline the company’s operations and governance as it moves forward under its new name.
Read more →BDRXGeneral
March 2023 Midatech Pharma PLC ("Midatech" or the "Company") Further re : Notice of General Meeting - Correction of Typographical Errors Further to the announcement made on 8 March 2023 providing notice of a general meet
Midatech Pharma PLC has issued a correction regarding the typographical errors in the notice for its upcoming General Meeting scheduled for March 24, 2023. The company clarified that no new notice will be published, and the corrections will be made through a motion at the meeting. Shareholders will not receive a new Form of Proxy but can access the corrected version on the company’s website. Those who wish to amend their proxy instructions can do so through the prescribed method.
Read more →BDRXGeneral
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or as to what action you should take, you should immediately consult your stockbroker, bank ma
The document serves as an important communication to shareholders regarding upcoming actions and meetings. It emphasizes the need for shareholders to consult financial advisors for clarity on the contents and implications. Key topics include a proposed share consolidation and a recommendation for shareholder votes at the general meeting. The meeting is scheduled for March 24, 2023, with proxy forms enclosed for participation.
Read more →BDRXGeneral
February 2023 Midatech Pharma PLC ("Midatech" or the "Company") Closing of US$6.0 million Private Placement Change of Broker Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on i
Midatech Pharma PLC has successfully closed a private placement, raising approximately US$5.2 million after costs, through the issuance of 10,344,822 units. The funds will primarily support the clinical development of MTX110, a treatment for recurrent glioblastoma and DIPG. Additionally, the company has appointed Strand Hanson Limited as its new sole broker, with plans for a general meeting to grant new warrants to investors.
Read more →BDRXGeneral
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAP
Midatech Pharma PLC has successfully entered into agreements for a private placement to raise approximately US$6.0 million. This funding will support the development of their clinical asset MTX110 and is expected to provide sufficient working capital until December 2023. The company anticipates key updates, including results from a Phase I study in rare orphan Diffuse Intrinsic Pontine Glioma by Q2 2023 and initial data from a Phase I study in recurrent Glioblastoma by Q3 2023.
Read more →BDRXGeneral
January 2023 Midatech Pharma PLC ("Midatech" or the "Company") Result of General Meeting Appointment of Specialist Business Advisory Firm - Quantuma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technol
Midatech Pharma PLC held a General Meeting where shareholders passed only one of the ordinary resolutions, leading to the halt of a proposed acquisition and name change. The company is currently facing financial difficulties and requires alternative funding by mid-March 2023 to continue operations. To navigate these challenges, Midatech has appointed Quantuma Advisory Limited for contingency planning. The lack of passed resolutions significantly impacts the company's strategic direction and financial outlook, with a risk of administration looming if funding is not secured.
Read more →BDRXPhases
January 2023 Midatech Pharma PLC ("Midatech" or the "Company") Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
Midatech Pharma PLC has announced a planned dose escalation in the Phase 1 study of MTX-110 for recurrent glioblastoma following positive recommendations from the Data Safety Monitoring Board (DSMB). The initial patient treated showed no adverse events, allowing progression to a higher dose, expected to be the optimal concentration. The study aims to validate the safety and effectiveness of MTX-110, which allows direct tumor delivery for better therapeutic outcomes. Enrollment will continue with additional patients receiving the escalated dosage in the coming weeks.
Read more →BDRXGeneral
INFORMATION RELATING TO MIDATECH Midatech Business Midatech is focused on the research and development of medicines which it believes would benefit from improved bio-delivery and/or bio-distribution using its proprietary
Midatech continues to advance its research and development efforts in drug delivery technologies, highlighting the potential benefits of their proprietary methods. The company had an important milestone as its MTX110 program received Fast Track designation from the U.S. FDA, aimed at expediting its development for treating recurrent glioblastoma. Additionally, there is ongoing compliance with NASDAQ listing requirements after a previous noteworthy challenge regarding share price. The recent changes in the ADS ratio were implemented to maintain compliance with NASDAQ's regulations.
Read more →BDRXGeneral
THIS DOCUMENT AND THE ENCLOSED FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document and/or the action you should take, you are recommended to seek
The document emphasizes its importance for shareholders regarding participating in the upcoming General Meeting. It details the procedures for voting on resolutions, including a proposed acquisition of Bioasis Technologies Inc. and a conditional private placement to raise US$9.6 million. Shareholders are urged to consult financial advisors if uncertain about the content or actions to take, reflecting the document's complexity and potential legal restrictions on its distribution.
Read more →BDRXGeneral
Explanatory Note On
On December 13, 2022, Midatech
Pharma plc (the "Company," "Midatech," "we," "our" or "us") announced it had
entered into an arrangement agreement (the "Arrangement Agreement") with Bioasis Technologies Inc., a corporation existing
under the laws of British Columbia, Canada ("B
Read more →BDRXPhases
November 2022 Midatech Pharma PLC ("Midatech" or the "Company") First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
("Midatech" or the "Company")
First Patient Enrolled in Phase 1 Study of MTX-110
(MAGIC-G1 Study) in Patients with
Recurrent Glioblastoma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
an R&D biotechnology company focused on improving the bio-delivery and biodistribution of
Read more →BDRXGeneral
September 2022 Midatech Pharma PLC ("Midatech" or the "Company") ADR Ratio Change Midatech Pharma (AIM: MTPH; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medici
("Midatech" or the "Company")
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), an R&D
biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a ratio change on its American
Depositary Receipts ("ADR") from one (1) ADR representing five
Read more →BDRXGeneral
June 2022 Midatech Pharma PLC ( Midatech or the Company ) Directorate Change Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medic
Midatech Pharma PLC (AIM:
MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased
to announce the appointment of Dr Stephen Parker as a Director of the Company and Non-Executive Chairman of the Board
Read more →BDRXGeneral
June 2022 Midatech Pharma PLC ("Midatech" or the "Company") Retirement of Chairman and Proposed Appointment of New Chairman Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improvin
("Midatech" or the "Company")
Retirement of Chairman and Proposed Appointment
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman
and non-exec
Read more →BDRXFDA Updates
June 2022 Midatech Pharma PLC ("Midatech" or the "Company") Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechn
("Midatech" or the "Company")
Fast Track Designation Granted to MTX110 Development
for the Treatment of Recurrent Glioblastoma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines,
Read more →BDRXGeneral
April 2022 Midatech Pharma PLC ("Midatech" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2021 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug
("Midatech" or the "Company"
or, together with its subsidiaries, the "Group")
Preliminary Results for the Year Ended 31 December
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology
company focused on improving the bio-delivery and biodistribution of med
Read more →BDRXGeneral
April 2022 Midatech Pharma PLC ("Midatech" or the "Company"") Receipt of NASDAQ Notice Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistr
("Midatech" or the "Company"")
Receipt of NASDAQ Notice
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received
written notification (the "Notificatio
Read more →BDRXGeneral
March 2022 Midatech Pharma PLC ("Midatech" or the "Company") Midatech announces R&D collaboration with Janssen on a second molecule Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused
("Midatech" or the "Company")
Midatech announces R&D collaboration with
Janssen on a second molecule
Midatech Pharma PLC (AIM: MTPH; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce
Read more →BDRXGeneral
January 2022 Midatech Pharma PLC ("Midatech" or the "Company") Midatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technology Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery t
("Midatech" or the "Company")
Midatech announces extension of R&D collaboration
with Janssen focused on
Midatech Pharma PLC (AIM: MTPH; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to annou
Read more →BDRXGeneral
December 2021 Midatech Pharma PLC ("Midatech" or the "Company") Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a d
("Midatech" or the "Company")
Investigational New Drug Application for Study
in Recurrent Glioblastoma (GBM) Becomes Effective
Midatech Pharma PLC (AIM: MTPH; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicin
Read more →BDRXPhases
September 2021 Midatech Pharma Plc ("Midatech" or the "Company") Interim results for the six months ended 30 June 2021 Midatech Pharma PLC (AIM: MTPH.L; NASDAQ: MTP), a drug delivery technology company focused on improvi
for the six months ended 30 June 2021
PLC (AIM: MTPH.L; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines,
announces its unaudited interim results for the six months ended 30 June 2021.
the Company announced
Read more →BDRXGeneral
June 2021 Midatech Pharma PLC ("Midatech" or the "Company") Result of 2021 Annual General Meeting Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery a
("Midatech" or the "Company")
Result of 2021 Annual General Meeting
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its
Annual General Meeting (AGM) he
Read more →BDRXGeneral
June 2021 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN W
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR
IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANN
Read more →BDRXGeneral
June 2021 Midatech Pharma PLC ("Midatech" or the "Company") Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes Midatech Pha
("Midatech" or the "Company")
Breakthrough data on the successful encapsulation
of a biologic using Q-Sphera technology
Significant progress across multiple other R&D
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
an R&D biotechnology company focused on improving the bio-de
Read more →BDRXGeneral
April 2021 Midatech Pharma PLC ("Midatech" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2020 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug
or the "Company" or, together with its subsidiaries, the "Group")
for the Year Ended 31 December 2020
PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines,
announces its audited preliminary re
Read more →BDRXGeneral
March 2021 Midatech Pharma PLC ("Midatech" or the "Company") Non-binding Heads of Terms for MTX110 Co-development of MTX110 and Unaudited Headline Results for the Year Ended 31 December 2020 Midatech Pharma PLC (AIM: MTP
("Midatech" or the "Company")
Non-binding Heads of Terms for MTX110 Co-development
Unaudited Headline Results for the Year Ended
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),
a drug delivery technology company focused on improving the bio-delivery and biodistribution of med
Read more →BDRXGeneral
January 2021 Midatech Pharma PLC ("Midatech" or the "Company") Business Update Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of med
("Midatech" or the "Company")
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a number
The Q-Sphera R&D pipeline
has expanded to a net five active projects with all
Read more →BDRXConferences/Events
December 2020 Midatech Pharma PLC ("Midatech" or the "Company") MTX110 Programmes to be Presented at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan (ISPNO 2020) Midatech Pharma PLC (AIM: MTPH.L
("Midatech" or the "Company")
MTX110 Programmes to be Presented
The International Symposium on Pediatric
Neuro-Oncology, Karuizawa, Japan (ISPNO 2020)
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on improving the bio-delivery and biodi
Read more →BDRXPhases
November 2020 Midatech Pharma PLC ("Midatech" or the "Company") MTX110 Phase I Trial Results in DIPG and Preclinical Efficacy Data in Glioblastoma presented at 2020 Annual SNO Conference Midatech Pharma PLC (AIM: MTPH.L;
("Midatech" or the "Company")
MTX110 Phase I Trial Results in DIPG
Preclinical Efficacy Data in Glioblastoma
at 2020 Annual SNO Conference
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution o
Read more →BDRXPhases
October 2020 Midatech Pharma PLC ("Midatech" or the "Company") Headline Results of MTX110 Phase I DIPG Study Phase II Dose Confirmed and Encouraging Survival Data Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D bi
("Midatech" or the "Company")
Headline Results of MTX110 Phase I DIPG
Phase II Dose Confirmed and Encouraging
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to ann
Read more →BDRXPhases
September 2020 Midatech Pharma Plc ("Midatech" or the "Company") Interim results for the six months ended 30 June 2020 R&D Collaboration Strategy Gaining Traction Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug de
("Midatech" or the "Company")
Interim results for the six months ended
R&D Collaboration Strategy Gaining
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution
of medicines, announces its
Read more →BDRXGeneral
August 2020 Midatech Pharma PLC ("Midatech" or the "Company") Exercise of Warrants and Issue of Equity Total Voting Rights Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on imp
("Midatech" or the "Company")
Exercise of Warrants and Issue
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that
it has issued to certain US investors 500,000
Read more →BDRXGeneral
August 2020 Midatech Pharma PLC ("Midatech" or the "Company") Registration Statement on Form F-1 Declared Effective May 2020 UK Warrants Now Exercisable Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery tec
("Midatech" or the "Company")
Statement on Form F-1 Declared Effective
May 2020 UK Warrants Now Exercisable
Midatech Pharma PLC (AIM: MTPH.L;
Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces
th
Read more →BDRXGeneral
July 2020 Midatech Pharma PLC ("Midatech" or the "Company") Result of 2020 Annual General Meeting Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery a
("Midatech" or the "Company")
Result of 2020 Annual General Meeting
Midatech Pharma PLC (AIM: MTPH.L;
Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces
that at its Annual General Meeting (AGM) he
Read more →BDRXGeneral
July 2020 Midatech Pharma PLC ("Midatech" or the "Company") Broker Option Fully Exercised and Total Voting Rights Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving th
("Midatech" or the "Company")
Broker Option Fully Exercised
PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of
medicines, announces that it has raised 0.75 million (before expenses) pursuant to a Brok
Read more →BDRXGeneral
July 2020 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN W
NOT FOR PUBLICATION, DISTRIBUTION OR
RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF
SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANN
Read more →BDRXGeneral
July 2020 Midatech Pharma PLC ("Midatech" or the "Company") Corporate Update and Termination of "Formal Sale Process" Midatech (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-d
("Midatech" or the "Company")
Termination of "Formal Sale Process"
Midatech (AIM: MTPH.L; Nasdaq: MTP), a
drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces it has
terminated the formal sale process initiated by
Read more →BDRXGeneral
July 2020 Midatech Pharma PLC ("Midatech" or the "Company") Midatech adds to collaborative business model for the Q-Sphera platform Midatech Pharma's next generation drug delivery technologies to be applied to new modali
("Midatech" or the "Company")
Midatech adds to collaborative business
model for the Q-Sphera platform
Midatech Pharma's next generation
drug delivery technologies to be applied to new modalities in collaboration with a European
pharmaceutical company.
Cardiff, UK, 21 July 2
Read more →BDRXGeneral
June 2020 Midatech Pharma Plc ("Midatech" or the "Company") Preliminary results for the year ended 31 December 2019 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving
("Midatech" or the "Company")
Preliminary results for the year ended
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and bio-distribution of medicines announces its audited preliminary results
for the ye
Read more →BDRXGeneral
This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is now considered to be in the public domain. 9 Ju
This Announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is
now considered to be in the public domain.
("Midatech" or the "Company")
Purported Termination of MTX11
Read more →BDRXGeneral
June 2020 Midatech Pharma PLC ("Midatech" or the "Company") Midatech enters into research collaboration with Dr Reddy's Laboratories Ltd (Dr Reddy's") Midatech Pharma's next generation drug delivery technologies for comp
("Midatech" or the "Company")
Midatech enters into research collaboration
with Dr Reddy's Laboratories Ltd (Dr Reddy's")
Midatech Pharma's next generation
drug delivery technologies for comprehensively improving bio-delivery and bio-distribution to be applied to existing medi
Read more →BDRXGeneral
May 2020 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company f
PLC Announces Closing of US$3.0 Million Registered Direct Offering
PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products
to patients, today announced the closing of its previously announced registered di
Read more →BDRXGeneral
May 2020 Midatech Pharma PLC ("Midatech" or the "Company") Amendment to Relationship Agreement Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and
("Midatech" or the "Company")
Amendment to Relationship Agreement
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that
China Medical System Holdings Ltd (0867.
Read more →BDRXGeneral
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDI
NOT FOR RELEASE, PUBLICATION
OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
IS AN ANNOUNCEMENT UNDER RULE 2.4 OF THE CITY CODE
Read more →BDRXGeneral
March 2020 Midatech Pharma PLC ("Midatech" or the "Company") Announcement of Strategic Review Termination of R&D Programme Update on EU GlioKIDS Grant Directorate Changes Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a
("Midatech" or the "Company")
Announcement of Strategic Review
Termination of R&D Programme
Update on EU GlioKIDS Grant
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patient
Read more →BDRXGeneral
March 2020 Midatech Pharma PLC ("Midatech" or the "Company") Result of General Meeting ADR Ratio Change Total Voting Rights Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on deliveri
("Midatech" or the "Company")
Result of General Meeting
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces
that all resolutions were passed at a general meetin
Read more →BDRXGeneral
February 2020 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces posting of Circular convening a General Meeting Share Consolidation and ADR Ratio Change Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
("Midatech" or the "Company")
Midatech Pharma announces posting of
Circular convening a General Meeting
Share Consolidation and
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to
Read more →BDRXGeneral
January 2020 Midatech Pharma PLC ("Midatech" or the "Company") Positive results from MTD201-102 Study Supports Subcutaneous Route for Long-Acting Octreotide Product Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D
("Midatech" or the "Company")
Positive results from MTD201-102 Study
Supports Subcutaneous Route for Long-Acting Octreotide Product
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products
Read more →BDRXGeneral
December 2019 Midatech Pharma PLC ("Midatech" or the "Company") Receipt of NASDAQ Notice Midatech (AIM: MTPH, NASDAQ: MTP) , an R&D biotechnology company focused on delivering innovative oncology and rare disease product
MTPH, NASDAQ: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products,
announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"),
dated 11 December 2019, stating that th
Read more →BDRXGeneral
December 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces confirmation of a 2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine G
("Midatech" or the "Company")
Midatech Pharma announces confirmation
of a 2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma,
a rare and fatal form of childhood brain cancer
Midatech Pharma PLC (AIM: MTPH.L; N
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Total Voting Rights Midatech (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to
("Midatech" or the "Company")
MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients,
announces total voting rights following the closing of its registered direct offering in the US of 3,000,000 America
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech's MTX110 Receives Orphan Designation for DIPG Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering inn
("Midatech" or the "Company")
Midatech's MTX110 Receives Orphan Designation
PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products
to patients, is pleased to announce that the U.S. Food and Drug Administ
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology compa
("Midatech" or the "Company")
Midatech Pharma PLC Announces Closing
of US$3.0 Million Registered Direct Offering
PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products
to patients, today announced the c
Read more →BDRXPhases
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Commencement of MTD201 Phase 1 Study Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare di
("Midatech" or the "Company")
Commencement of MTD201 Phase 1 Study
Midatech (AIM: MTPH.L; NASDAQ: MTP), the
R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that further
to the announcement made on 20 Septemb
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Issue of Equity for Midatech Employee Share Incentive Plan Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on deliverin
("Midatech" or the "Company")
Issue of Equity for Midatech Employee
Share Incentive Plan
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today
announces that, condi
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ("Midatech" or the "Company") PDMR Dealing Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patien
("Midatech" or the "Company")
Midatech (AIM: MTPH.L; NASDAQ: MTP), the
R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that
Stephen Stamp, Chief Financial Officer and a Director of the Company, has purchased
Read more →BDRXGeneral
October 2019 Midatech Pharma PLC ( Midatech or the Company ) Award of Options to a Director Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease pr
(AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products
to patients, announces that an award has been made under the 2014 Midatech Pharma plc Enterprise Management Incentive Scheme to
Stephen Stamp, Chief Fin
Read more →BDRXPhases
Midatech will host a conference call and live Q&A session today (Monday 30 September 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the 2019 Interim Results. Dr Craig Cook, Chief Executive Officer, an
Midatech will host a conference call
and live Q&A session today (Monday 30 September 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the 2019
Interim Results. Dr Craig Cook, Chief Executive Officer, and Stephen Stamp, Chief Financial Officer, will lead the pr
Read more →BDRXGeneral
September 2019 A shelf registration statement has been filed with the United States Securities and Exchange Commission, but has not yet become effective. Any offers, solicitations of offers to buy, or sales of these secu
A shelf registration statement has been
filed with the United States Securities and Exchange Commission, but has not yet become effective. Any offers, solicitations of
offers to buy, or sales of these securities will only be made once the shelf registration statement has been d
Read more →BDRXFDA Updates
September 2019 Midatech Pharma PLC ("Midatech" or the "Company") MTD201 Phase 1 Study Approval Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and r
("Midatech" or the "Company")
MTD201 Phase 1 Study Approval
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased
to announce it has received approval to commen
Read more →BDRXGeneral
September 2019 Midatech Pharma PLC ("Midatech" or the "Company") Receipt of Spanish Government Loan for the scale up of MTD201 commercial manufacturing facility Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D bio
("Midatech" or the "Company")
Receipt of Spanish Government Loan for
MTD201 commercial manufacturing facility
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is plea
Read more →BDRXGeneral
September 2019 Midatech Pharma PLC ("Midatech" or the "Company") Directorate Change Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease
("Midatech" or the "Company")
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased
to announce the appointment of Stephen Stamp as a Director of the Company and
Read more →BDRXGeneral
July 2019 Midatech Pharma PLC ("Midatech" or the "Company") Appointment of Non-Executive Director Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology an
("Midatech" or the "Company")
Appointment of Non-Executive Director
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased
to announce the appointment of Fr d ri
Read more →BDRXGeneral
July 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Positive Safety Results from First in Human Study for Injectable MidaCore Gold Nano Particle Diabetes Vaccine Programme - MTX102 Midatech Pha
("Midatech" or the "Company")
Midatech Announces Positive Safety Results
from First in Human Study for Injectable MidaCore Gold Nano Particle Diabetes Vaccine Programme - MTX102
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative o
Read more →BDRXGeneral
July 2019 Midatech Pharma PLC ("Midatech" or the "Company") MTX110 Update Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, i
("Midatech" or the "Company")
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D
company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce an update on its
key MTX110 programme.
MTX110 is designed for the treatment of
Read more →BDRXGeneral
June 2019 Midatech Pharma PLC ("Midatech" or the "Company") Result of AGM Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, i
("Midatech" or the "Company")
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce
that all resolutions were passed at the Annual General Meeting held earlier tod
Read more →BDRXGeneral
June 2019 Midatech Pharma PLC ("Midatech" or the "Company") MTD201 Development Plan Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to p
("Midatech" or the "Company")
MTD201 Development Plan
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce
that it has finalised the development plan for its key
Read more →BDRXGeneral
May 2019 Midatech Pharma PLC ("Midatech" or the "Company") Posting of Annual Report & Notice of AGM Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disea
("Midatech" or the "Company")
Posting of Annual Report & Notice
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, announces that its Notice
of Annual General Meeting ("AGM") was pos
Read more →BDRXConferences/Events
Midatech will host a conference call and live Q&A session today (Wednesday 24 April 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the Full Year 2018 Results. Dr Craig Cook, Chief Executive Officer, a
Midatech will host a conference call and live Q&A session today (Wednesday
24 April 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the Full Year 2018 Results. Dr Craig Cook, Chief Executive
Officer, and Nick Robbins-Cherry, Chief Financial Officer, will lead
Read more →BDRXFDA Updates
March 2019 Midatech Pharma PLC ("Midatech" or the "Company") Approval received for Spanish Government Loan for the scale up of MTD201 commercial manufacturing facility Midatech today announces that on 28th March 2019, th
received for Spanish Government Loan for the scale up of
commercial manufacturing facility
Midatech today announces that on 28th March 2019, the Spanish government notified the Company that it has provisionally approved
the Company's Reindustrialisation ("Reindus") loan applic
Read more →BDRXGeneral
March 2019 Midatech Pharma PLC ("Midatech" or the "Company") ADR Ratio Change Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, ann
("Midatech" or the "Company")
Midatech Pharma (AIM: MTPH; Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, announces a ratio change on
its American Depositary Receipts ("ADR") from one (1) ADR representing two (2) o
Read more →BDRXGeneral
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION I
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN OR THE REPUBLIC
OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE
Read more →BDRXGeneral
February 2019 Midatech Pharma PLC ("Midatech", "Company" or "Group") Posting of Circular and Notice of General Meeting Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology a
("Midatech", "Company"
Posting of Circular and Notice of General
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, confirms that following the
Result of Placing announcement on 4 February
Read more →BDRXGeneral
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. 29 January 2019 Midatech Pharma PLC ("Midatech", "Company" or "Group") Strategic Investment to Raise 8 mill
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014.
("Midatech", "Company"
Strategic Investment to Raise 8
Licence Agreement for the Greater China
Area and certain South East Asian Countries
Proposed Grant of Warr
Read more →BDRXFDA Updates
January 2019 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech receives FDA feedback on clinical plan for MTD201 Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative on
("Midatech", "Company"
Midatech receives FDA feedback on clinical
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that
further to its announcement on 20 December
Read more →BDRXFDA Updates
January 2019 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech announces EUR 1.5 million loan facility for manufacturing site - Basque Regional Government approves loan facility to support manufacturing fac
("Midatech", "Company"
Midatech announces EUR 1.5 million loan facility
for manufacturing site
Midatech Pharma (AIM:
MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients,
today announces that further to the Compa
Read more →BDRXGeneral
December 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech Announces Q-Sphera Microsphere Technology Partnership - Collaboration agreed with major regional pharmaceutical company - Midatech's leading t
("Midatech", "Company"
Midatech Announces Q-Sphera Microsphere
Technology Partnership
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D
company focused on delivering innovative oncology and rare disease products to patients, today announces an agreement with a major
regional
Read more →BDRXGeneral
November 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Completion of Midatech Pharma US Sale Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare dise
("Midatech", "Company"
Completion of Midatech Pharma US Sale
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that,
further to recent Company updates, the proposed
Read more →BDRXGeneral
November 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") NASDAQ Minimum Bid Price Extension Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease
("Midatech", "Company"
NASDAQ Minimum Bid Price Extension
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company
focused on delivering innovative oncology and rare disease products to patients, announces that, as previously disclosed, on 1
May, 2018, Midatech Pharma PLC (t
Read more →BDRXGeneral
October 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Result of General Meeting Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products
("Midatech", "Company"
Result of General Meeting
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that
the resolution concerning shareholder approval of the sale o
Read more →BDRXGeneral
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank ma
THIS DOCUMENT IS IMPORTANT
AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek
your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent
financi
Read more →BDRXGeneral
September 2018 Midatech Pharma PLC ("Midatech" or the "Company") Posting of Circular and Notice of General Meeting Midatech Pharma Plc (AIM: MTPH, NASDAQ: MTP) is pleased to announce that further to the announcement date
("Midatech" or the "Company")
Posting of Circular and Notice of
Midatech Pharma Plc (AIM: MTPH, NASDAQ: MTP) is pleased
to announce that further to the announcement dated 27 September 2018 regarding the proposed sale of Midatech Pharma US Inc, the
Company will today be postin
Read more →BDRXPhases
August 2018 Midatech Pharma PLC ( Midatech or the Company ) Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera Microsphere Technology - Interim d
("Midatech" or the "Company")
Midatech Announces Interim Results
from Proof of Concept Exploratory Study for its
MTD201 Q-Octreotide Programme
and Q-Sphera Microsphere Technology
Midatech Pharma PLC (AIM: MTPH,
Nasdaq: MTP), the international specialty pharmaceutical compan
Read more →BDRXGeneral
August 2018 Issue of Equity for Midatech Share Incentive Plan Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology an
Issue of Equity for Midatech Share Incentive
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy,
today announces that, conditional on admission to trading
Read more →BDRXGeneral
July 2018 Trading Update Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces a tr
Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising
products in oncology and immunotherapy, today announces a trading update for the six months ended 30 June 2018.
Company remains on track to deliver fina
Read more →BDRXGeneral
July 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal to the Oncology Market i
("Midatech", "Company" or "Group")
Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal to the Oncology Market in United States
- NeutraSal indicated for Xerostomia, a highly prevalent cancer treatmen
Read more →BDRXPhases
June 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant - Patients now being enrolled at the Dana-Farber/Brigham and Women's Canc
("Midatech", "Company" or "Group")
Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant
- Patients now being enrolled at the Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
Read more →BDRXGeneral
June 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") 2017 Annual Report and AGM Notification Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and com
("Midatech", "Company" or "Group")
2017 Annual Report and AGM Notification
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, is pleased to confirm that the 2017
Read more →BDRXPhases
May 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the interna
("Midatech", "Company" or "Group")
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising produ
Read more →BDRXPhases
May 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly - Initial dosing administered in pote
("Midatech", "Company" or "Group")
Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialis
Read more →BDRXGeneral
May 2018 Midatech Pharma PLC ("Midatech" or the "Company") Statement regarding share price movement Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty pharmaceutical company focused on developing and commerc
("Midatech" or the "Company")
Statement regarding share price movement
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, notes the recent movement in the Company's share price an
Read more →BDRXConferences/Events
Midatech will host a conference call and live Q&A session today (Monday 23 April 2018) at 1400 BST / 0900 EDT for analysts and investors to discuss the Full Year 2017 Results. Dr Craig Cook, Chief Executive Officer-desig
Midatech will host a conference call and live Q&A session today (Monday 23 April 2018) at 1400 BST / 0900 EDT for analysts and investors to discuss the Full Year 2017 Results. Dr Craig Cook, Chief Executive Officer-designate, and Nick Robbins-Cherry, Chief Financial Officer, will
Read more →BDRXGeneral
April 2018 Midatech Pharma PLC ("Midatech" or the "Company") Notice of Preliminary Results Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty pharmaceutical company focused on developing and commercialising
("Midatech" or the "Company")
Notice of Preliminary Results
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces that it will release its prelimina
Read more →BDRXGeneral
March 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech announces changes in Senior Management Team Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty pharmaceutical company focused on developi
("Midatech" or the "Company")
Midatech announces changes in Senior Management Team
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces that Dr Jim
Read more →BDRXFDA Updates
February 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty phar
("Midatech" or the "Company")
Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today anno
Read more →BDRXGeneral
February 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading update Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products
("Midatech", "Company" or "Group")
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today provides a trading update ahead of its full year results for the twelve months ended 31
Read more →BDRXFDA Updates
January 2018 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech and UCSF receive IND approval for DIPG treatment MTX110 - First treatment in patients in US expected as scheduled in Q1 2018 Midatech Pharma (A
("Midatech", "Company" or "Group")
Midatech and UCSF receive IND approval for DIPG treatment MTX110
- First treatment in patients in US expected as scheduled in Q1 2018
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on deve
Read more →BDRXFDA Updates
January 9018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved Midatech (AIM: MTPH, Nasdaq: MTP) , the international speci
("Midatech" or the "Company")
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology,
Read more →BDRXGeneral
January 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech enters into a Loan Agreement with MidCap Financial Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty pharmaceutical company focused on
("Midatech" or the "Company")
Midatech enters into a Loan Agreement with MidCap Financial
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, is pleased to announce that it has ent
Read more →BDRXPhases
December 2017 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma US initiates Gelclair Phase IV trial to study oral mucositis in stem cell transplant patients Trial to be conducted at the Dana-Farber / Bri
("Midatech" or the "Company")
Midatech Pharma US initiates Gelclair Phase IV trial to study oral mucositis in stem cell transplant patients
Trial to be conducted at the Dana-Farber / Brigham and Women's Cancer Center to determine ability to improve OM outcomes and reduce overal
Read more →BDRXGeneral
November 2017 Midatech Pharma PLC ("Midatech" or the "Company") Midatech receives manufacturing certification from Spanish regulatory authority Scaled up manufacturing is complete at Bilbao facility's centre of excellenc
("Midatech" or the "Company")
Midatech receives manufacturing certification from Spanish regulatory authority
Scaled up manufacturing is complete at Bilbao facility's centre of excellence
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical comp
Read more →BDRXGeneral
November 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Issue of Equity for Midatech Pharma Share Incentive Plan Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company f
("Midatech", "Company" or "Group")
Issue of Equity for Midatech Pharma Share Incentive Plan
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and related t
Read more →BDRXGeneral
October 2017 Midatech Pharma PLC ("Midatech" or the "Company") Result of Open Offer, Result of General Meeting and Issue of Equity Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical comp
("Midatech" or the "Company")
Result of Open Offer,
Result of General Meeting
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, announces the
Read more →BDRXGeneral
September 2017 Midatech Pharma PLC ("Midatech" or the "Company") Results of Placing to raise 6 million and PDMR Shareholding 2:26 p.m. (BST): Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmace
("Midatech" or the "Company")
Results of Placing to raise 6 million
2:26 p.m. (BST): Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and related therapeu
Read more →BDRXGeneral
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNI
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA,
Read more →BDRXPhases
September 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Notice of interim results Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and comme
("Midatech", "Company" or "Group")
Notice of interim results
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that it will release its interim results for
Read more →BDRXGeneral
September 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly Midatech on track to start clinical development with MT
("Midatech", "Company" or "Group")
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
Midatech on track to start clinical development with MTD201 in Q4 2017
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharma
Read more →BDRXGeneral
July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Completion of pre-clinical liver cancer programme Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on d
("Midatech", "Company" or "Group")
Completion of pre-clinical liver cancer programme
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces the successful compl
Read more →BDRXGeneral
Execution Copy CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk ("[***]") to
CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk ("[***]") to denote where omissions have been made. The confidential material has been f
Read more →BDRXGeneral
July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading Update and Notice of Results Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and
("Midatech", "Company" or "Group")
Trading Update and Notice of Results
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces a trading update and provides not
Read more →BDRXGeneral
June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") R&D manufacturing site visit for investors and analysts Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focuse
("Midatech", "Company" or "Group")
R&D manufacturing site visit for investors and analysts
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, is hosting a site visit today
Read more →BDRXGeneral
June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the internatio
("Midatech", "Company" or "Group")
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products
Read more →BDRXGeneral
May 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech announces progress update on brain cancer therapies Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company fo
("Midatech", "Company" or "Group")
Midatech announces progress update on brain cancer therapies
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, announces that it has sel
Read more →BDRXGeneral
May 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Issue of Equity for Midatech Pharma Share Incentive Plan Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focuse
("Midatech", "Company" or "Group")
Issue of Equity for Midatech Pharma Share Incentive Plan
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, today announces the issue and
Read more →BDRXGeneral
May 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Result of Annual General Meeting Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and
("Midatech", "Company" or "Group")
Result of Annual General Meeting
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, announces that at its Ann
Read more →BDRXConferences/Events
Midatech will host a conference call and live Q&A session today (Tuesday 4 April 2017) at 1400 BST / 0900 EDT for analysts and investors to discuss the Annual Results. Dr Jim Phillips, Chief Executive Officer, and Nick R
Midatech will host a conference call and live Q&A session today (Tuesday 4 April 2017) at 1400 BST / 0900 EDT for analysts and investors to discuss the Annual Results. Dr Jim Phillips, Chief Executive Officer, and Nick Robbins-Cherry, Chief Financial Officer, will participate. Di
Read more →BDRXGeneral
March 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Notice of Preliminary Results Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and
("Midatech", "Company" or "Group")
Notice of Preliminary Results
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announces
Read more →BDRXGeneral
March 2017 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility ~ Q-Octreotide will become Midatech's first Sustained Release pr
("Midatech" or the "Company")
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
~ Q-Octreotide will become Midatech's first Sustained Release product candidate manufactured in house at its state-of-the-art facility in Bilbao, Spain ~
Read more →BDRXGeneral
February 2017 Midatech Pharma PLC ("Midatech" or the "Company") Midatech enters into a Loan Agreement with Silicon Valley Bank Midatech (AIM: MTPH, Nasdaq: MTP) , the international specialty pharmaceutical company focuse
("Midatech" or the "Company")
Midatech enters into a Loan Agreement with Silicon Valley Bank
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, is pleased to announce that it has
Read more →BDRXGeneral
January 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading Update Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising pr
("Midatech", "Company" or "Group")
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today provides a trading update ahead of its full year results for the twelve months en
Read more →BDRXGeneral
December 2016 Midatech Pharma PLC ("Midatech" or the "Company") Director/PDMR Shareholding Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercial
("Midatech" or the "Company")
Director/PDMR Shareholding
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, announces that today, 20 December 2016, certain PDMRs purchased
Read more →BDRXGeneral
November 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech provides update on agreement with Emergex Vaccines Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company foc
("Midatech" or the "Company")
Midatech provides update on agreement with Emergex Vaccines
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that following
Read more →BDRXGeneral
November 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech selects MTR104 candidate for treatment of liver cancer Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company
("Midatech" or the "Company")
Midatech selects MTR104 candidate for treatment of liver cancer
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, has today announced that, f
Read more →BDRXGeneral
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRA
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY
Read more →BDRXGeneral
August 2016 Midatech Pharma PLC ("Midatech" or the "Company") Trading Update and Notice of Results Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising a
("Midatech" or the "Company")
Trading Update and Notice of Results
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announce
Read more →BDRXGeneral
July 2016 Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising
Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeuti
Read more →BDRXGeneral
June 2016 Annual Report Posting Midatech Pharma (AIM: MTPH; Nasdaq: MTP) announces that, in accordance with AIM Rules 19 & 20, the Company's Annual Report and Accounts for the year ended 31 December 2015 and its notice t
Annual Report Posting
Midatech Pharma (AIM: MTPH; Nasdaq: MTP) announces that, in accordance with AIM Rules 19 & 20, the Company's Annual Report and Accounts for the year ended 31 December 2015 and its notice to convene the Company's Annual General Meeting ("AGM") were published
Read more →BDRXGeneral
June 2016 Midatech Pharma PLC ("Midatech" or the "Company") Issue of Equity and Director's Dealings Issue of Equity Midatech Pharma (AIM: MTPH; Nasdaq: MTP) , the international specialty pharmaceutical company focused on
("Midatech" or the "Company")
Issue of Equity and Director's Dealings
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces the iss
Read more →BDRXGeneral
May 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces clinical pipeline update Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commer
("Midatech" or the "Company")
Midatech Pharma announces clinical pipeline update
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announ
Read more →BDRXGeneral
May 2016 Midatech Pharma PLC ("Midatech" or the "Company") AGM Statement and Update on Trading Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and d
("Midatech" or the "Company")
AGM Statement and Update on Trading
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today will host its Annual
Read more →BDRXGeneral
April 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide ~ Release profile of Midatech's Q-Octreotide compared favourably with the reference p
("Midatech" or the "Company")
Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the interna
Read more →BDRXPhases
April 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech achieves positive dosing data for OpsiSporin Uveitis programme ~ Programme is delivering on track for an IND in H2 2017 ~ Midatech Pharma (AIM: MTPH;
("Midatech" or the "Company")
Midatech achieves positive dosing data for OpsiSporin Uveitis programme
~ Programme is delivering on track for an IND in H2 2017 ~
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialis
Read more →BDRXConferences/Events
Midatech will host a conference call and live Q&A session today (Wednesday 13 April 2016) at 1300 BST / 0800 EDT for analysts and investors to discuss the Annual Results. Dr Jim Phillips, Chief Executive Officer, and Nic
Midatech will host a conference call and live Q&A session today (Wednesday 13 April 2016) at 1300 BST / 0800 EDT for analysts and investors to discuss the Annual Results. Dr Jim Phillips, Chief Executive Officer, and Nick Robbins-Cherry, Chief Financial Officer, will participate.
Read more →BDRXGeneral
April 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech's Commercial Launch of Zuplenz (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US
("Midatech" or the "Company")
Midatech's Commercial Launch of Zuplenz (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US
- Midatech further expands its commercial footprint in US, supporting the Zuplenz launch
Read more →BDRXGeneral
March 2016 Midatech Pharma PLC ("Midatech", the "Company" or the "Group") Notice of Audited Full Year Results and Adoption of Financial Reporting Standard (FRS) 102 - Reduced Disclosure Framework Midatech Pharma (AIM: MT
("Midatech", the "Company" or the "Group")
Notice of Audited Full Year Results
Adoption of Financial Reporting Standard (FRS) 102 - Reduced Disclosure Framework
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing a
Read more →BDRXPhases
February 2016 Midatech Pharma PLC ("Midatech", the "Company" or the "Group") Midatech Pharma Recognises International Rare Disease Day 2016 ~ Dosing has commenced with MTX110 for DIPG on a named patient basis ~ Midatech
("Midatech", the "Company" or the "Group")
Midatech Pharma Recognises International Rare Disease Day 2016
~ Dosing has commenced with MTX110 for DIPG on a named patient basis ~
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused
Read more →BDRXGeneral
For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi Woodford Investment Management LLP as Investment Manager Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder
Read more →BDRXGeneral
January 2016 Midatech Pharma PLC ( Midatech , the Company or the Group ) Pre-close Trading Update Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and com
( Midatech , the Company or the Group )
Pre-close Trading Update
(AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, today announces a trading update ahead of it
Read more →BDRXGeneral
January 2016 Midatech Pharma PLC ( Midatech or the Company ) Midatech signs licencing agreement with Emergex Vaccines Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused o
( Midatech or the Company )
Midatech signs licencing agreement with Emergex Vaccines
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology
and other therapeutic areas, today a
Read more →BDRXGeneral
December 2015 Midatech Pharma PLC ( Midatech or the Company ) Issue of Equity Midatech (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in on
( Midatech or the Company )
Midatech (AIM: MTPH;
Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, today announces the issue and allotment of 224,719 new ordinary shares o
Read more →BDRXGeneral
December 2015 Midatech Pharma PLC ( Midatech or the Company ) Midatech agrees to acquire marketed oncology product, Zuplenz , from Galena Biopharma, Inc. ~Zuplenz (ondansetron) oral soluble film prevents post-operative,
( Midatech or the Company )
Midatech agrees to acquire marketed oncology product, Zuplenz , from Galena
~Zuplenz (ondansetron) oral soluble film prevents
post-operative, chemotherapy- and radiation-induced nausea and vomiting~
Midatech Pharma (AIM: MTPH), the international sp
Read more →BDRXGeneral
December 2015 Midatech Pharma PLC ( Midatech or the Company ) Midatech signs supply agreement with Centurion Pharma ~ Q-Octreotide license agreement in Turkey further expands the international and commercial outlook of M
( Midatech or the Company )
Midatech signs supply agreement with Centurion Pharma
~ Q-Octreotide license agreement in Turkey further expands the international and commercial outlook of Midatech ~
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the specialty pharmaceutical company fo
Read more →BDRXGeneral
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Midatech Pharma
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
( Midatech , the Company or the Group )
Successful Completion of Acquisit
Read more →